Xilio Therapeutics Stifel 2026 Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Hey, guys. We're going to get started here. For this fireside chat, we have Xilio Therapeutics. René, CEO, Yariv, CMO, and Uli, CSO, which is probably for the best that we have all three of you guys, because I do want to get a little bit more into some of the newer assets you guys are moving into the clinic soon and areas of differentiation. But maybe to start, if you guys can introduce us to yourselves. I know you're new, so it would be great to get a little bit of your background and what attracted you to this company, and just where you guys are as a company, where you are as far as clinical progress and milestones upcoming in 2027.
Great. So maybe I'll kick off, and then we can go down. So hi, everyone. I'm René Russo, president and CEO of Xilio Therapeutics. We're a protein engineering company focused on masked IO therapies. We have just put our fourth IND. Our fourth IND just got cleared in mid-year, and we put our fourth program into the clinic, which is a PD-1 masked IL-2 that we're very excited about. The quickest way to kind of give the update on the history of the company is we have clinically validated masking technology. We started out with simple molecules, monoclonal antibodies, and cytokines, demonstrated in the clinic activation in patient tumors with these molecules, and have multiple pharma partnerships, including two active ones with Gilead and AbbVie, based on that validation of our initial molecules.
Now, coming up in 2027, we're moving into these more complex multispecifics, again, starting with the PD-1/IL-2, and also masked T-cell engagers that incorporate multi-targeting and co-stimulatory signaling built into the molecule. So we'll talk a little bit more about what's coming up in 2027.
Hi, everyone. I'm Uli Bialucha, chief scientific officer at Xilio Therapeutics. I'm a cancer biologist by training. I'm a strong believer in immunotherapy. I think the field generally appreciates that immunotherapy can drive profound responses in cancer patients, but that oftentimes we're limited by how high we can dose. So the therapeutic index is a challenge that we've been geared up to solve at Xilio Therapeutics, and as you will learn today, we're doing so across a variety of therapeutics in development.
Hi, everyone. I'm Yariv Houvras. I'm a physician scientist and medical oncologist. I joined Xilio two months ago. My prior experience in drug development includes T-cell engagers and ADCs in solid and hematologic malignancies. I was really delighted to join Xilio because I think they have best-in-class protein engineering in IO, and I think we really have a tremendous opportunity to bring safe and effective medicines to patients with advanced solid tumors.
Thank you. Great. Maybe to start with XTX501, your IL-2 PD1.
Can you maybe as we start getting into the whole masking, talk about learnings that you guys have from your previous assets and what you think the importance and the differentiation of masking such an asset is here?
Yeah, absolutely. I'll start, and everyone can jump in. We've been working in the masking space for a while. We have a lot of experience masking cytokines, and we recognized pretty early on that putting a cytokine into a PD1 bispecific really was differentiated to really bring that cytokine to PD1-positive cells, in particular IL-2 with that known biology. But of course, IL-2 can be incredibly toxic, can have PK challenges, right, if it gets taken up in the peripheral circulation. So the masking is really key, and we've also now had the benefit of experience, I think, in the whole field that the right design for an IL-2 is not full beta-gamma, but is more of a wild-type IL-2 that has the right alpha tuning.
It's a combination of the potency of the IL-2, the alpha in the IL-2, and the masking that allows it to have long half-life and activation on the PD1-positive cells in the tumor. That's the key. Would you like to add anything, Uli?
Maybe just adding that the field obviously has had or has pursued IL-2 for a while, and it's never been a challenge around IL-2 not being relevant to T-cell biology. I'd argue it's a key pathway, and we know that if you deliver IL-2, this T-cell agonism can drive profound responses. The challenge has always been around how you engineer it so that it has the right receptor bias, that you can give it in a tolerated way, and then more recently, an appreciation that driving it to the right cell type is really critical.
That's what we're really aiming to do with 501, drive the IL-2 to the PD1-positive T cells that we know are enriched for antigen-specific T cells that are seeing and fighting the tumor, keeping it in check in the periphery using the mask, and then when it's in the tumor microenvironment, remove the mask efficiently and allow for the right receptor bias, right? So that you get, again, more preferential activity on those PD1-positive recently activated T cells that also have the alpha receptor.
A lot of learnings have gone into the design of this molecule, and I think based on our preclinical profiling, even in relative to Innovent's IBI363, we have a high conviction that this has a best-in-class potential.
Compared to Innovent's data to date, when you guys look at that data, in what areas do you think you could clinically differentiate, and I guess, what will you be looking for in your early dataset next year?
Maybe I'll just kind of start out that I think we're all very excited about what we've seen with the IBI363 data, in particular, really meaningful efficacy in the post-PD1 setting, which is very exciting, right? And we think these type of molecules have the potential, right, to really move up earlier line and ideally, right, move to become the next pembro, right? Become the foundational backbone. What you need though in order to do that is you need excellent tolerability, so it can be as early line. You need to be able to combine it, and you need the efficacy, right, to really be driven as far as possible, even in the post-PD1 setting. So, Uli, do you want to talk about what we Sure are hoping to see here?
Yeah. No, I think, just to build off your comments, I believe that XTX501 may be a next-generation PD-1/IL-2, because of multiple design features and the rigorous preclinical evidence that was generated. XTX501 is bivalent for PD1, whereas IBI363 is monovalent. So we know we're a stronger binder at PD1. We have an alpha-optimized IL-2, with significantly stronger affinity and activation of the IL-2 receptor, and we're masked. We're fully masked, and the preclinical evidence demonstrates really nicely that the masked molecule has minimal activity and unmasked is very potent at inducing tumor regressions in vivo. I think all of this will translate into safety and efficacy in our first clinical trial, which has started. We enrolled our first patients several weeks ago.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
